offline
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.30 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 40.50%. A quarter ago, it was expected that this drugmaker would post earnings of $1.14 per share when it actually produced earnings of $1.23, delivering a surprise of 7.89%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Vertex, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.41 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 41.36%. This compares to year-ago revenues of $870.11 million.
...
https://finance.yahoo.com/news/vertex-ph...10940.html
![[Bild: VRTXc1dl1450.png]](https://finviz.com/publish/020320/VRTXc1dl1450.png)
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.30 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 40.50%. A quarter ago, it was expected that this drugmaker would post earnings of $1.14 per share when it actually produced earnings of $1.23, delivering a surprise of 7.89%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Vertex, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.41 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 41.36%. This compares to year-ago revenues of $870.11 million.
...
https://finance.yahoo.com/news/vertex-ph...10940.html
__________________
